Keywords
TEG
coagulation system disorders
How to Cite
Abstract
In press
Background. COVID-19 is a leading disease in terms of prevalence (more than 100 million cases) and mortality (more than 10.0%). Most often, COVID-19 is accompanied by hemostatic disorders (manifestations of COVID-19-associated coagulopathy) and blood coagulation.
Aim. To determine the levels of correlation between clinical and laboratory characteristics of hemostatic and coagulation disorders (according to the characteristics of ThromboElastoGraphy, TEG) in patients with COVID-19 infection.
Materials and Methods. The study was performed at the Department of Infectious and Pediatric Infectious Diseases, Parasitology, Phthisiology and Pulmonology of Kharkiv National Medical University in accordance with the existing recommendations of bioethical norms and rules. All patients signed an informed consent. 179 patients with COVID-19 were examined. The levels of correlation between laboratory and instrumental characteristics were determined using Spearman's rank correlation coefficient. The probability of differences was determined using the Mann-Whitney U-test.
Results & Conclusions. According to the results of the study, significant direct and inverse correlations were found. The identified correlations determined the possible interaction between TEG parameters and the characteristics of the systemic inflammatory response. The obtained results play a significant role for patients with COVID-19, because they can predict shifts in inflammatory systemic response parameters, which characterize the severity of the disease, based on the characteristics of TEG. The interrelationships of hemostatic and coagulation system disorders have been reliably determined by the presence of significant correlations between the characteristics of the inflammatory systemic response of patients with COVID-19 and TEG values. The obtained significant correlations were mostly weak, but there were also interdependencies of medium strength. In particular, Interleukin-6 and some other indicators on days 5–6 after hospitalization.
Keywords: thromboelastography, TEG, coagulation system disorders.
Archived: https://doi.org/10.5281/zenodo.12582880
References
Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-40. DOI: 10.1182/blood.2020006000. PMID: 32339221.
Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438-40. DOI: 10.1016/S2352-3026(20)30145-9. PMID: 32407672.
Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19. N Engl J Med. 2020;383(2):120-8. DOI: 10.1056/NEJMoa2015432. PMID: 32437596.
Miesbach W, Makris M. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Clin Appl Thromb Hemost. 2020;26:1076029620938149. DOI: 10.1177/1076029620938149. PMID: 32677459.
Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res. 2020;192:152-60. DOI: 10.1016/j.thromres.2020.05.039. PMID: 32485418.
McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. Circ Res. 2020;127(4):571-87. DOI: 10.1161/CIRCRESAHA.120.317447. PMID: 32586214.
Ahmed S, Zimba O, Gasparyan AY. Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad. Clin Rheumatol. 2020;39(9):2529-43. DOI: 10.1007/s10067-020-05275-1. PMID: 32654082.
Schulman S. Coronavirus Disease 2019, Prothrombotic Factors, and Venous Thromboembolism. Semin Thromb Hemost. 2020;46(7):772-6. DOI: 10.1055/s-0040-1710337. PMID: 32392613.
Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L. Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge. Thromb Haemost. 2020;120(6):949-56. DOI: 10.1055/s-0040-1710317. PMID: 32349133.
Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, Wang Y. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis. 2020;99:47-56. DOI: 10.1016/j.ijid.2020.07.029. PMID: 32721533.
McBane RD 2nd, Torres Roldan VD, Niven AS, Pruthi RK, Franco PM, Linderbaum JA. Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance from Mayo Clinic. Mayo Clin Proc. 2020;95(11):2467-86. DOI: 10.1016/j.mayocp.2020.08.030. PMID: 33153635.
Chekkal M, Deba T, Hadjali S, Lamara H, Oulaa H, Zouai K, Hariti G. Prevention and treatment of COVID-19-associated hypercoagulability: Recommendations of the Algerian society of transfusion and hemobiology. Transfus Clin Biol. 2020;27(4):203-6. DOI: 10.1016/j.tracli.2020.09.004. PMID: 33022374.
Franchini M, Marano G, Cruciani M, Mengoli C, Pati I, Masiello F. COVID-19-associated coagulopathy. Diagnosis (Berl). 2020;7(4):357-63. DOI: 10.1515/dx-2020-0078. PMID: 32683333.
Brown W, Lunati M, Maceroli M, Ernst A, Staley C, Johnson R, Schenker M. Ability of Thromboelastography to Detect Hypercoagulability: A Systematic Review and Meta-Analysis. J Orthop Trauma. 2020;34(6):278-86. DOI: 10.1097/BOT.0000000000001714. PMID: 31815829.
Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: A systematic review and meta-analysis. Rev Med Virol. 2020;30(6):1-9. DOI: 10.1002/rmv.2141. PMID: 32845568.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.